Clinuvel is a profitable, cash-rich specialty biopharmaceutical company whose commercial model is anchored by SCENESSE, a first-in-class afamelanotide implant for ultra-rare EPP. The therapy prevents debilitating visible-light phototoxicity, supports more than 90% adherence and is distributed directly through 129 US accredited centers and European expert centers. **The existing franchise has produced ten consecutive annual profits, but it is mature and concentrated: SCENESSE contributes approximately 100% of product revenue.** FY2026 ordinary-activities revenue declined 1.0% to A$94.024 million, total revenue and other income fell 4.0% to A$101.153 million, and NPAT declined 6.0% to A$33.917 million; nevertheless, net margin remained 36%. Cash rose 12.0% to A$252.055 million, the company has zero debt, and NTA per share increased to A$5.35. At A$10.60, market capitalization is approximately A$534.5 million and EV is A$282.4 million, equivalent to 2.98x FY2026 total revenue and 5.9x operating profit. **The near-term catalyst is CUV105 vitiligo data expected in December 2026**, while a US relocation, potential Nasdaq primary listing and adolescent EPP expansion could improve strategic positioning. The principal risks are oral EPP competitors, restructuring execution and vitiligo failure.